Our History

We have established a track record of efficient and consistent achievement.

Our company was founded in 2017 with a vision of harnessing novel biology to develop therapeutics with a transformational, global impact on patients’ lives. We have made rapid progress toward that goal and pride ourselves on accurately projecting—and delivering—important milestones.
Ongoing Ph. 3 Studies

HARMONY Phase 2b Week 96 Study Readout

We reported topline week 96 data showing statistically significant histological improvements, demonstrating ≥1- and ≥2-stage fibrosis improvement without worsening of MASH at both 50mg and 28mg doses of EFX.

Public Follow-On Offering

Following topline week 96 HARMONY data, we closed a public offering with gross proceeds of approximately $366.9M.


Public Offering

$334.8 million in net proceeds raised through Akero’s ATM Facility and underwritten registered direct offering of common stock.

SYMMETRY Cohort D Readout

Results from the expansion cohort of the Phase 2b SYMMETRY study met safety and tolerability endpoints and showed adding EFX to GLP-1 therapy significantly improved non-invasive markers of MASH, offering benefit over GLP-1 therapy alone.

SYMMETRY Phase 2b Week 36 Readout

We reported results from a 36-week analysis of the Phase 2b SYMMETRY study of EFX in F4 patients which showed a trend on fibrosis improvement, which was not statistically significant, and statistically significant results for MASH resolution, markers of liver injury and fibrosis, insulin sensitization and lipoproteins.

Phase 3 SYNCHRONY Program Initiated

We initiated and dosed the first patients in two parallel, randomized, placebo-controlled Phase 3 trials: SYNCHRONY Histology evaluating the efficacy and safety of EFX in patients with biopsy-confirmed pre-cirrhotic MASH, and SYNCHRONY Real-World assessing safety and tolerability of EFX in patients with non-invasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD).


HARMONY Phase 2b Study Readout

Our topline Ph 2b data achieved statistical significance on both primary and secondary histology endpoints after 24 weeks in patients with pre-cirrhotic MASH (F2-F3).

Upsized Public Follow-On Offering

Following topline HARMONY data, we closed an upsized underwritten public offering with gross proceeds of approximately $230M.

Breakthrough Therapy Designation

Lead candidate EFX was granted Breakthrough Therapy Designation from the US FDA for the treatment of MASH.


BALANCED Expansion Cohort Readout

We reported early evidence that EFX has the potential to reverse fibrosis for cirrhotic MASH patients.

Phase 2b HARMONY and SYMMETRY Study Initiation

Parallel studies in pre-cirrhotic and cirrhotic MASH are the next step toward a potential commercialization of EFX, if approved.

employees and growing

Phase 2a BALANCED Study Readouts

Our topline liver fat, liver injury, metabolic and biopsy data showed strongly positive and consistent improvements across multiple parameters for MASH.

$216M Upsized Follow-On Offering

Our cumulative financing surpassed $400M with an upsized follow-on offering at the top of the marketing range.

New Corporate Headquarters

We completed renovation of our new corporate headquarters in South San Francisco, CA.


$106M Upsized IPO

We closed an upsized IPO at the top of the range just a year after obtaining our first biotech asset.

First Patient Dosed in BALANCED Study

An experienced team and efficient execution enabled rapid entry to the clinic to evaluate EFX in MASH.


$45M Series A Financing and Amgen License

We entered an exclusive, global license from Amgen to develop EFX, backed by blue-chip investors.

$45.5M Series B Financing

Our crossover financing with a dozen top-tier private investors paved the way for a successful IPO.

Manufacturing Partnerships

We partnered with Boehringer-Ingelheim and Vetter Pharma to ensure high quality API and drug product.

We are led by a savvy team of biopharma industry veterans.

We are led by a savvy team of biopharma industry veterans.